Activation of c-Myc uncouples DNA replication from activation of G1-cyclin-dependent kinases

Proto-oncogenes like c-myc are thought to control exit from the cell cycle rather than progression through the cell cycle itself. We now present a different view of Myc function. Exponentially growing Rat1-MycER fibroblasts were size-fractionated by centrifugal elutriation. In these cells, activatio...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 15; no. 6; pp. 649 - 656
Main Authors PUSCH, O, BERNASCHEK, G, EILERS, M, HENGSTSCHLÄGER, M
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing 07.08.1997
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Proto-oncogenes like c-myc are thought to control exit from the cell cycle rather than progression through the cell cycle itself. We now present a different view of Myc function. Exponentially growing Rat1-MycER fibroblasts were size-fractionated by centrifugal elutriation. In these cells, activation of cyclin E- and cyclin A-dependent kinases, degradation of p27, hyperphosphorylation of retinoblastoma protein and activation of E2F occur sequentially at specific cell sizes. Upon activation of Myc, however, these transitions all occur simultaneously in small cells immediately after exit from mitosis. In contrast, Myc has no discernible effect on the cell size at which DNA replication is initiated. These data show first that Myc controls the activity of G1 cyclin-dependent kinases independently from the transition between quiescence and proliferation and from any effect on cell growth in size. These data also provide evidence of at least one dominant mechanism besides activation of E2F and of cyclin E/cdk2 kinase, which prevents DNA replication unless a critical cell size has been reached.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0950-9232
1476-5594
DOI:10.1038/sj.onc.1201236